[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368276-105":59,"doc-detail-368276-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","chimeric-antigen-receptor-t-cells-in-colorectal-cancer-review-articles-avenues-in-solid-tumor-immunotherapy","Chimeric Antigen Receptor-T Cells in Colorectal Cancer - Review Articles - Avenues in Solid Tumor Immunotherapy","","Colorectal cancer (CRC) remains a major global health burden with high mortality, and metastatic disease often has limited therapeutic options and poor outcomes despite advances in surgery, chemotherapy, and radiation. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, is evaluated here for CRC as a promising solid-tumor immunotherapy approach. The review synthesizes clinical trials, emphasizes CRC-specific targets, and details obstacles including immunosuppressive microenvironment, tumor heterogeneity, and physical barriers, while discussing logic-gated, dual-targeting, and checkpoint inhibitor combinations to improve persistence and infiltration.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chimeric-antigen-receptor-t-cells-in-colorectal-cancer-review-articles-avenues-in-solid-tumor-immunotherapy/368276/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chimeric-antigen-receptor-t-cells-in-colorectal-cancer-review-articles-avenues-in-solid-tumor-immunotherapy/368276.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is CAR-T cell therapy considered for colorectal cancer despite limited options for metastatic disease?","Question",{"text":113,"@type":114},"CAR-T therapy has shown strong activity in hematologic malignancies and offers a promising strategy for targeting solid tumors like CRC. The review highlights its potential to expand the therapeutic landscape where current approaches often fall short for metastatic cases.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What key barriers limit CAR-T efficacy in CRC?",{"text":118,"@type":114},"The review emphasizes the immunosuppressive tumor microenvironment, tumor heterogeneity, and physical barriers. These factors reduce effective CAR-T activity and limit durable tumor control.",{"name":120,"@type":111,"acceptedAnswer":121},"How do emerging strategies aim to improve CAR-T performance in CRC?",{"text":122,"@type":114},"The document discusses logic-gated and dual-targeting CAR-T designs to address targeting challenges. It also explores combining CAR-T with immune checkpoint inhibitors to enhance T-cell persistence and tumor infiltration.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368276,1790410325,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review Articles  \nChimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy  \nShaida Ouladan, MD, PhD, MSc1  and Elias Orouji, MD, PhD2  DOI [https://doi.org/10.1200/JCO-24-02081](https://doi.org/10.1200/JCO-24-02081)  \nABSTRACT  \nColorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the potential of CAR-T cell therapy in CRC by analyzing clinical trials and highlighting prominent CRCspeciﬁc targets. We discuss the challenges such as immunosuppressive microenvironment, tumor heterogeneity, and physical barriers that limit CAR-T efﬁcacy. Emerging strategies, such as logic-gated and dual-targeting CAR-T cells, offer practical solutions to overcome these hurdles. Furthermore, we explore the combination of CAR-T cell therapy with immune checkpoint inhibitors to enhance T-cell persistence and tumor inﬁltration. As the ﬁeld continues to evolve, CAR-T cell therapies hold signiﬁcant potential for revolutionizing the treatment landscape of CRC.  \nAccepted December 11, 2024 Published January 13, 2025  \nJ Clin Oncol 43:994-1005 © 2025 by American Society of Clinical Oncology  \nView Online Article  \nLicensed under the Creative  \nCommons Attribution 4.0 License  \nINTRODUCTION  \nColorectal cancer (CRC) is a signiﬁcant global health challenge, being the third most common cancer and the second leading cause of cancer-related deaths worldwide.1 ,2 Traditional treatment modalities such as surgery, chemotherapy, and radiation therapy, although effective in many cases, often fall short for patients with advanced or metastatic CRC.3 In recent years, immunotherapy has emerged as a promising avenue, with chimeric antigen receptor-T (CART) cell therapy being one of these innovative treatments.4,5  \nCAR-T cell therapy genetically modiﬁes a patient’s T cells to target cancer cells by inserting a CAR.6,7 The process involves collecting T cells, activating them, genetically modifying them with a CAR to recognize tumor-speciﬁc antigens, expanding the modiﬁed cells, and reintroducing them into the patient after lymphodepleting preconditioning to enhance tumor targeting (Fig 1) .8-13  \nOriginally developed and approved for hematologic malignancies, CAR-T cell therapy has shown remarkable success in treating diseases such as ALL and diffuse large B-cell lymphoma.14,15 This success has spurred signiﬁcant interest in adapting CAR-T cell therapy for solid tumors, including CRC.16  \nA CAR consists of an extracellular single-chain variable fragment (scFv) domain that binds antigens, a hinge for ﬂexibility, a transmembrane domain to anchor it to the T cell, and intracellular signaling domains for T-cell  \nactivation.17,18 First-generation CARs use CD3z for signaling, while second- and third-generation CARs include costimulatory domains (ie, CD28 or 4-1BB) to enhance T-cell activity and persistence, making them potent tools in cancer immunotherapy.19,20  \nThis review aims to present a comprehensive overview of CAR-T cell therapy inCRC, focusing on emerging therapeutic targets, key clinical trials, and challenges. It critically assesses recent advancements and explores the potential of CAR-T cell therapy to alter the therapeutic paradigm for CRC.  \nADVANCEMENTS IN ANTIGEN SELECTION FOR CRC CAR-T CELL THERAPIES  \nIntroducing speciﬁc targets for CAR-T cell therapy in CRC is essential for enhancing the efﬁcacy and speciﬁcity of the treatment. These targets are carefully selected based on their expression on CRC cells and minimal presence on normal tissues to reduce off-tumor toxicity.21 Here, we discuss several key targets for CAR-","cbCaipllqqqadtO6","https://ap.wps.com/l/cbCaipllqqqadtO6","pdf",788746,13,"English","# Abstract\n# Introduction\n## CAR-T cell therapy workflow and rationale\n# Advancements in Antigen Selection for CRC CAR-T Cell Therapies\n## Carcinoembryonic Antigen (CEA)\n## Clinical trial experiences and safety signals","[{\"question\":\"Why is CAR-T cell therapy considered for colorectal cancer despite limited options for metastatic disease?\",\"answer\":\"CAR-T therapy has shown strong activity in hematologic malignancies and offers a promising strategy for targeting solid tumors like CRC. The review highlights its potential to expand the therapeutic landscape where current approaches often fall short for metastatic cases.\"},{\"question\":\"What key barriers limit CAR-T efficacy in CRC?\",\"answer\":\"The review emphasizes the immunosuppressive tumor microenvironment, tumor heterogeneity, and physical barriers. These factors reduce effective CAR-T activity and limit durable tumor control.\"},{\"question\":\"How do emerging strategies aim to improve CAR-T performance in CRC?\",\"answer\":\"The document discusses logic-gated and dual-targeting CAR-T designs to address targeting challenges. It also explores combining CAR-T with immune checkpoint inhibitors to enhance T-cell persistence and tumor infiltration.\"}]","Chimeric Antigen Receptor-T Cells in Colorectal Cancer - Review Articles - Avenues in Solid Tumor Immunotherapy | PDF",1790175990,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/868fe96daeaa3613bb8f9f5a6b5119b4.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6b2601d2cc1f0f25079417d5c41f742.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04078fe2a66794a3bdc2afcd885dacdd.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7653fa361239619dcf43a6fb83a3e464.webp",980,1311]